The Doctor and The Athlete: Powerhouse Duo Disrupts Functional Beverage Market with Science-Backed “Happiness”
FUGO Precision 3D to Debut Revolutionary Centrifugal 3D Printing Technology with Live Demonstrations at LMT LAB DAY Chicago 2026
The Micro-Mechanics of Modern Oral Care
Dr. Shahrooz Yazdani Launches $6M Dental Practice Seminar Series to Help Owners Break Free from Burnout
New Aura and UNC-Chapel Hill Study Finds One in Three Kids Have Accessed GenAI Apps
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in...
Figure 1 Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer. New York, N.Y.,...
~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~ SAN DIEGO, CALIFORNIA / ACCESS...
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare MarketingCAMPBELL, Calif. and NEW YORK, Jan....
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand...
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate...
Peer-Reviewed Paper Confirms Cavadex Drives Plummeting Coronary Artery Calcium Scores : Reversing the Irreversible ROBINA AND QUEENSLAND, AUSTRALIA / ACCESS...
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for...
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record...
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused...
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building...
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10...
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613...
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan....
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with...
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company,...
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...
DENVER, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in...
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)...
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the...
